Shares of GPC Biotech Inc., partner Pharmion Corp., and licensee Spectrum Pharmaceuticals Inc. continued to sink Tuesday as an FDA advisory panel debated the merits of satraplatin for second-line, hormone-refractory prostate cancer, in a closely watched case that had investors nervous because of briefing papers posted last week on the agency's website. (BioWorld Today) Read More
